September 12, 2013
In high-income countries such as Canada, Australia and the U.S. and in regions such as Western Europe, the widespread availability of potent combination anti-HIV therapy (commonly called ART or HAART) has greatly reduced deaths due to AIDS-related infections. Furthermore, some researchers are predicting that a young HIV-positive adult who begins ART today and who does not have major co-morbidities -- such as smoking, co-infection with viral hepatitis, mental health issues, substance use -- is likely to live for several decades, perhaps, in some cases, even experiencing a near-normal lifespan.
Researchers conducting experiments in the lab have found that HIV can infect some cells in the kidney. Studies in HIV-positive people have found that they are at risk for increased kidney injury and, over time, in some cases, impaired functioning of these vital organs. The kidneys perform many important functions, including filtering the blood of wastes and producing urine, regulating blood pressure, monitoring the level of oxygen in the blood and helping convert vitamin D to its active form.
In cases where untreated HIV infection causes kidney dysfunction, commencing ART generally results in improvement of overall health and kidney health in particular.
There have been reports of an elevated risk of kidney injury and dysfunction among some HIV-positive people who used the older anti-HIV drug indinavir (Crixivan). However, this drug is seldom used in high-income countries today. There have also been reports of kidney injury occurring among some users of the newer anti-HIV medicines atazanavir (Reyataz) and tenofovir (Viread, and found in Truvada, Atripla, Complera and Stribild). More information about these issues appears later in this bulletin as well as in the resources section.
Researchers in Denmark have been monitoring the health of more than 5,000 HIV-positive people for up to 15 years. They compared data collected from HIV-positive people to that collected from more than 50,000 HIV-negative people of the same age and gender. Over the 15 years of the study the researchers found that there was an increased risk (nearly five-fold) among HIV-positive people of developing serious kidney injury -- requiring temporary or permanent dialysis -- compared to HIV-negative people.
Further results from this study, including risk factors for serious kidney injury and the possible impact of HIV treatment on kidney health, appear later in this CATIE News bulletin.
For some time now, Danish researchers have established a high-quality data set containing health-related information from both HIV-positive and HIV-negative people. This allows researchers to analyse the data for trends in health-related issues.
In the present analysis, data from 5,300 HIV-positive people were compared to data from 53,000 HIV-negative people. Specifically, data from each HIV-positive person was compared to data from 10 HIV-negative people of the same age and gender.
The average profile of the HIV-positive participants at the start of the study was as follows:
Presence of co-morbidities that could impact kidney health:
Distribution of eGFR (estimated glomerular filtration rate -- one method for assessing kidney health) where an eGFR greater than 90 is considered healthy and less than 60 is considered seriously abnormal:
Note that eGFR for 43% of participants at the start of the study was not available.
During the study, 68 HIV-positive participants required at least temporary dialysis. Among HIV-negative participants, the figure was 182 people. This suggests that HIV-positive people were at nearly five-fold increased risk for serious kidney injury. This difference was statistically significant.
The need for dialysis was greatest in the 12 months after an HIV diagnosis.
Among the 68 HIV-positive people who required dialysis at least once, 28% had kidney health that grew worse over time and ultimately required dialysis on a regular basis.
Among HIV-positive people, the risk factors for serious kidney injury requiring a round of dialysis were as follows:
Risk factors for needing chronic dialysis were as follows:
In participants who used tenofovir, atazanavir or both drugs, there was no significant impact on kidney health. This was the case even when researchers restricted their analysis to the past decade, when atazanavir and tenofovir became available.
Researchers explained that doctors who cared for patients in the study knew about the potential for drugs such as atazanavir and tenofovir to cause kidney injury and dysfunction. These doctors, the researchers argued, would not have been likely to prescribe atazanavir or tenofovir (or both) to patients with kidney dysfunction. Furthermore, should kidney dysfunction have appeared, doctors would have discontinued these drugs. These practices may have helped reduce the risk of kidney injury and the need for dialysis among patients who took those medicines.
No comments have been made.